Clinical Trial

68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients

Unknown Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 5, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. Lung cancer tissues express fibroblast activating protein FAP, and also have high expression of integrin αVβ3 receptor on the surface of blood vessels. In this study, a novel dual-target imaging agent 68Ga-FAPI-RGD was used for PET/CT imaging of lung cancer.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05543954
Lead Sponsor Peking Union Medical College Hospital
Conditions Lung Neoplasms
Enrollment 60 participants
Start Date 2022-09-03
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-05